ACIU 财务： AC Immune SA AI 分析

Q: AC Immune SA 的关键财务报表是什么？

根据最新的财务报表（Form-10K），AC Immune SA 的总资产为 $230，净损失为 $-50

Q: ACIU 的关键财务比率是什么？

AC Immune SA 的流动比率是 1.94，净利 margin 为 -185.18，每股销售为 $0.27。

Q: AC Immune SA 的收入按细分市场或地理位置如何划分？

AC Immune SA 最大收入来源是 Therapeutic and Diagnostic Products，在最近的收益报告中收入为 31,009,430。就地区而言， Switzerland 是 AC Immune SA 的主要市场，收入为 31,009,430。

Q: AC Immune SA 是否盈利？

不，根据最新的财务报表，AC Immune SA 的净损失为 $-50

Q: AC Immune SA 有负债吗？

是的，AC Immune SA 的负债为 118

Q: AC Immune SA 的流通股有多少？

AC Immune SA 的总流通股为 100.41

主页

股票

ACIU

ACIU 财务

AC Immune SA

$3.51

-3.3%

$-0.12

收盘价：Jan 16, 16:00:00 GMT-5

$3.5

-0.28%

$0

盘后：Jan 16, 20:00:00 GMT-5

概述预测收益股息财务数据

关键数据

前收盘价

$3.63

开盘价

$3.6

当日区间

$3.47 - $3.67

52周范围

$1.43 - $4

交易量

186.6K

平均成交量

713.5K

每股收益（TTM）

-0.72

股息收益率

市值

$351.4M

什么是 ACIU？

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

功能特性

交易策略

资源

市场

收入

资产负债表

现金流量

年度

季度性

ACIU 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
营收	4	27	14	3	0	15
营收同比增长 (YoY)	-90%	93%	367%	--	-100%	-86%
营收成本	--	--	--	--	--	--
毛利润	--	--	--	--	--	--
销售、一般及管理费用	11	11	10	9	10	11
研发	61	62	54	60	62	59
营业费用	77	79	68	74	79	76
其他非经营性收入 (费用)	--	--	--	--	0	0
税前利润	-71	-50	-54	-70	-73	-61
所得税费用	0	0	0	0	0	0
净利润	-71	-50	-54	-70	-73	-61
净利润增长	82%	-7%	-23%	-4%	20%	-236%
稀释后流通股数	100.89	99.69	84.69	83.6	75	71.9
股份同比变动 (YoY)	0%	18%	1%	11%	4%	1%
每股收益 (摊薄)	-0.71	-0.51	-0.64	-0.85	-0.97	-0.86
每股收益增长率	75%	-20%	-25%	-12%	13%	-234%
自由现金流	-47	65	-61	-74	-68	-61
每股自由现金流	--	--	--	--	--	--
毛利率	--	--	--	--	--	--
营业利润率	-1,825%	-192.59%	-378.57%	-2,333.33%	0%	-406.66%
净利率	-1,775%	-185.18%	-385.71%	-2,333.33%	0%	-406.66%
自由现金流利润率	-1,175%	240.74%	-435.71%	-2,466.66%	0%	-406.66%
EBITDA	-71	-50	-51	-68	-77	-60
EBITDA 利润率	-1,775%	-185.18%	-364.28%	-2,266.66%	0%	-400%
EBITDA 中的折旧与摊销	2	2	2	2	2	1
EBIT	-73	-52	-53	-70	-79	-61
EBIT 利润率	-1,825%	-192.59%	-378.57%	-2,333.33%	0%	-406.66%
有效税率	0%	0%	0%	0%	0%	0%

Follow-Up Questions

AC Immune SA 的关键财务报表是什么？



ACIU 的关键财务比率是什么？



AC Immune SA 的收入按细分市场或地理位置如何划分？



AC Immune SA 是否盈利？



AC Immune SA 有负债吗？



AC Immune SA 的流通股有多少？



AC Immune SA（ACIU）价格

ACIU 股价走势图